Inhibrx, Inc. INBX
We take great care to ensure that the data presented and summarized in this overview for Inhibrx, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding INBX
View all-
Viking Global Investors LP7.15MShares$108 Million0.95% of portfolio
-
Perceptive Advisors LLC New York, NY4.26MShares$64.2 Million3.12% of portfolio
-
Black Rock Inc. New York, NY2.75MShares$41.5 Million0.0% of portfolio
-
State Street Corp Boston, MA2.42MShares$36.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.86MShares$28.1 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA1.75MShares$26.4 Million6.44% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA1.3MShares$19.7 Million2.65% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.2MShares$18.2 Million0.01% of portfolio
-
Alpine Associates Management Inc. Englewood Cliffs, NJ1.05MShares$15.9 Million1.44% of portfolio
-
Arrow Mark Colorado Holdings LLC Denver, CO891KShares$13.4 Million0.39% of portfolio
Latest Institutional Activity in INBX
Top Purchases
Top Sells
About INBX
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Insider Transactions at INBX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 30
2024
|
Viking Global Investors LP |
SELL
Other acquisition or disposition
|
Indirect |
7,150,826
-100.0%
|
$214,524,780
$30.0 P/Share
|
|
May 30
2024
|
Brendan P. Eckelman Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
2,055,553
-100.0%
|
$61,666,590
$30.0 P/Share
|
|
May 30
2024
|
Douglas Forsyth Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
598,257
-100.0%
|
$17,947,710
$30.0 P/Share
|
|
May 30
2024
|
Jon Faiz Kayyem Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
3,274,301
-100.0%
|
$98,229,030
$30.0 P/Share
|
|
May 30
2024
|
Mark Lappe Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
3,045,654
-100.0%
|
$91,369,620
$30.0 P/Share
|
|
May 28
2024
|
Brendan P. Eckelman Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
300,000
-14.74%
|
$10,200,000
$34.3 P/Share
|
|
Aug 28
2023
|
Viking Global Investors LP |
BUY
Open market or private purchase
|
Indirect |
511,627
+50.0%
|
$9,720,913
$19.35 P/Share
|
|
Mar 01
2023
|
Brendan P. Eckelman Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
40,000
-0.96%
|
$960,000
$24.46 P/Share
|
|
Feb 28
2023
|
Mark Lappe Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
60
-0.0%
|
$1,500
$25.02 P/Share
|
|
Feb 02
2023
|
Brendan P. Eckelman Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
11,250
-0.27%
|
$281,250
$25.65 P/Share
|
|
Feb 01
2023
|
Brendan P. Eckelman Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
28,750
-0.45%
|
$718,750
$25.01 P/Share
|
|
Jan 24
2023
|
Mark Lappe Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
4,335
-0.09%
|
$108,375
$25.91 P/Share
|
|
Jan 23
2023
|
Mark Lappe Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
21,665
-0.86%
|
$541,625
$25.36 P/Share
|
|
Jan 23
2023
|
Jon Faiz Kayyem Director |
SELL
Open market or private sale
|
Indirect |
9,500
-0.29%
|
$237,500
$25.26 P/Share
|
|
Jan 04
2023
|
Brendan P. Eckelman Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
7,105
-0.17%
|
$163,415
$23.55 P/Share
|
|
Jan 03
2023
|
Brendan P. Eckelman Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
32,895
-0.51%
|
$789,480
$24.29 P/Share
|
|
Dec 21
2022
|
Jon Faiz Kayyem Director |
SELL
Open market or private sale
|
Indirect |
9,500
-0.15%
|
$256,500
$27.24 P/Share
|
|
Dec 19
2022
|
Mark Lappe Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
26,000
-0.51%
|
$650,000
$25.91 P/Share
|
|
Dec 06
2022
|
Brendan P. Eckelman Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
40,000
-0.61%
|
$1,080,000
$27.62 P/Share
|
|
Nov 21
2022
|
Jon Faiz Kayyem Director |
SELL
Open market or private sale
|
Indirect |
9,500
-0.15%
|
$275,500
$29.73 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 512K shares |
|---|
| Sale (or disposition) back to the issuer | 8.97M shares |
|---|---|
| Open market or private sale | 300K shares |
| Other acquisition or disposition | 7.15M shares |